烏龍製藥 URGN 深 滬
已收盤 02-06 16:00:00 美东时间
21.35
+0.830
+4.04%
華盛通- 最 高21.77
- 今 開20.68
- 成交量 75.12万股
- 最 低 20.68
- 昨 收 20.52
- 總市值 9.99亿
- 52周最高 30.00
- 市盈率 靜 --
- 換手率 1.60%
- 52周最低 3.42
- 委 比 10.31%
- 總股本 4680.89万
- 歷史最高 69.568
- 量 比 0.98
- 振 幅 5.31%
- 歷史最低 3.42
- 每 手 1
- 風險率 5.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $33 Price Target
D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $33 price target.
01-23 20:52
UroGen Pharma shares are trading higher after the company announced that the permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI for intravesical solution became effective on January 1, 2026.
UroGen Pharma shares are trading higher after the company announced that the pe...
01-05 21:11
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
UroGen Pharma announced the permanent approval of J Code J9282 for ZUSDURI, a therapy for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). This code simplifies billing and reimbursement, reducing delays and improving patient access. ZUSDURI, the only FDA-approved nonsurgical treatment for this condition, uses UroGen’s RTGel technology for sustained release, offering a non-surgical chemoablative option. Provi...
01-05 13:00
美股周涨跌榜 | Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购
Capricor周涨402.6%，核心药物取得关键性临床试验进展；DBRG周涨45.4%，曝软银有意收购；UiPath本周上涨34.7%，财报表现强劲>>
2025-12-06 10:17
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. granted inducement RSUs to 14 new employees, supporting the commercialization of Jelmyto® and ZUSDURI™ and pipeline development. Up to 32,500 shares are issuable, vesting over three years. The RSUs align with UroGen’s commitment to advancing innovative urothelial cancer treatments.
2025-12-05 13:00
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
UroGen Pharma Ltd., a biotech company focused on developing innovative treatments for urothelial and specialty cancers, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2-4, 2025, in New York, NY. The company will host a fireside chat on December 2, 2025, at 1:00 PM ET. Webcast links and replays will be available on UroGen’s Investor Relations website for 90 days. UroGen specializes in creating sustai...
2025-11-25 13:00
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
Urogen Pharma ( ($URGN) ) has released its Q3 earnings. Here is a breakdown of ...
2025-11-07 13:54
UroGen Pharma Q3 EPS $(0.69), Inline, Sales $27.500M Miss $33.093M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.69) per share which met the analyst consensus estimate. This is a 25.45 percent decrease over losses of $(0.55) per share from the same period last year. The
2025-11-06 21:02
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
UroGen Pharma reported Q3 2025 financial results, highlighting strong performance of ZUSDURI with $1.8M net revenue and a $4.5M demand estimate in October. JELMYTO contributed $25.7M revenue, up 13% YoY. UGN-103 showed a 77.8% complete response rate, aligning with ENVISION results, with FDA agreement on NDA submission. Cash reserves stood at $127.4M. A conference call was scheduled for further updates.
2025-11-06 13:00
